"As a result of the research undertook in the MYCAP ERC project, Dr Martín del Valle’s team have developed a new smart nanoparticle for delivering cisplatin, which is the current lung cancer standard of care (SoC). In order to accelerate its market entry, the present “Proof of Concept” (PoC) project, named NANOSPART, will conduct in vitro validation of cisplatin nanoparticles through cell lines culture assays, as well as the technological optimization of the drug delivering system and the upper spray-based technology arisen from “MYCAP” ERC funded.The work undertaken so far requires further investment in applied research, in order to turn the outputs shown above into a commercial proposition. The NANOSMART project will make an important contribution towards the future pre-clinical and clinical phases, and new key industrial applications.Dr. Martín del Valle´s team have developed a new drug delivery system (DDS) for lung cancer treatment based on polymer nanoparticles, as a result of MYCAP project. Dr Martín del Valle now aims to progress this idea to PoC through the NANOSMART project, which has mainly three goals: defining the right chemical properties of these nanoparticles; determining the optimal dose of cisplatin-conjugates in relation to toxicity and efficacy parameters; In terms of expected outcomes, the project will contribute to meet critical market needs in lung cancer treatment. Globally, lung cancer is one of the most common types of cancer, with an estimated 1.2 million new cases being diagnosed every year. Despite the emergence of new treatments, 85% of lung cancer patients don’t survive, which is mainly due to metastatic disease . Because of the overall poor prognosis, new treatment strategies for lung cancer patients are urgently needed. Dr. Eva Martín del Valle and her team from University of Salamanca, are willing to address this issue with a new approach that utilises novel nanopartictechnology to deliver the current SoC (cisplatin)."